Haloperidol
- Generic Name
- Haloperidol
- Brand Names
- Haldol
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23ClFNO2
- CAS Number
- 52-86-8
- Unique Ingredient Identifier
- J6292F8L3D
- Background
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularl...
- Indication
Haloperidol is indicated for a number of conditions including for the treatment of schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of Tourette’s Disorder in children and adults, for treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted ...
- Associated Conditions
- Aggression, Delirium, Gilles de la Tourette's Syndrome, Huntington's Disease (HD), Nausea and vomiting, Obsessive Compulsive Disorder (OCD), Psychosis, Schizophrenia, Severe Disruptive Behaviour Disorders, Severe Hyperactivity
- Associated Therapies
- -
A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
- Conditions
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1234412
- Registration Number
- NCT04002700
- Locations
- 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States
Pharmacological Modulation of Belief Salience
- Conditions
- Interventions
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- King's College London
- Target Recruit Count
- 30
- Registration Number
- NCT03754062
- Locations
- 🇬🇧
Centre for Neuroimaging Sciences, London, United Kingdom
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 110
- Registration Number
- NCT03743649
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
🇧🇷Hosptial de Cancer de Barretos, Barretos, Sao Paulo, Brazil
Haloperidol for Delirium in Adult Critically Ill Patients
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 142
- Registration Number
- NCT03628391
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Netherlands
🇳🇱ErasmusMC, Rotterdam, Netherlands
🇳🇱Ikazia Hospital, Rotterdam, Netherlands
Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Michelle Weckmann
- Target Recruit Count
- 17
- Registration Number
- NCT03489551
Rapid Agitation Control With Ketamine in the Emergency Department
- Conditions
- Interventions
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- David Barbic
- Target Recruit Count
- 81
- Registration Number
- NCT03375671
- Locations
- 🇨🇦
St. Paul's Hospital Emergency Department, Vancouver, British Columbia, Canada
PROfylactic Haloperidol in Patients Defined as High Risk for DElirium With Delirium Risk mOdel
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Zuyderland Medisch Centrum
- Target Recruit Count
- 1366
- Registration Number
- NCT03199950
- Locations
- 🇳🇱
Zuyderland Medisch Centrum, Sittard, Limburg, Netherlands
Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2019-05-03
- Target Recruit Count
- 120
- Registration Number
- NCT03075657
- Locations
- 🇮🇳
All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT03021486
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department
- Conditions
- Interventions
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- OhioHealth
- Target Recruit Count
- 66
- Registration Number
- NCT02972502
- Locations
- 🇺🇸
OhioHealth Doctors Hospital, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.